Tom Vanden Berghe obtained his Master's and PhD in Science (Biotechnology) in 1999 and 2005, respectively. Following his doctoral studies, he pursued postdoctoral research at the VIB-UGent Center for Inflammation Research. In 2018, he was appointed as an Assistant Professor at the University of Antwerp and Guest Professor at Ghent University. He was promoted to Associate Professor in 2023 and, through a fast-track procedure, achieved the rank of Professor in 2024.
Professor Vanden Berghe is head of the Cell Death Signaling Lab at University of Antwerp. His mission is to conduct applied research focusing on cell death, particularly ferroptosis, pyroptosis (inflammation), and associated diseases. The Vanden Berghe Lab investigates mechanisms, diagnostics, and intervention strategies related to critical illnesses, brain injuries, kidney and vascular diseases. In addition, the team explores the potential of ferroptosis as a novel anti-cancer therapy for eliminating therapy-resistant cancers. Professor Vanden Berghe has established a comprehensive ferroptosis platform encompassing novel lead ferroptosis inhibitors and genes, ferroptosis diagnostics, and ferroptosis-based nanomedicine for anti-cancer therapeutics.
Professor @ UAntwerp
Guest Professor @ UGent
Research coordinator
10% ZAP
Vascular calcification
Postdoctoral fellow
10% ZAP
Kidney disease
Ferroptosis
Epigenetics
Ferroptosis
Chronic interstitial nephritis
Ferroptosis
Nonalcoholic fatty liver disease
Ferroptosis
Anti-cancer therapeutics
Ferroptosis
Chronic kidney disease
Ferroptosis
Ischemia/reperfusion injury
Ferroptosis
Mechanism lipid peroxidation
Endothelial cells
Vascular calcification
Nephrectomy
Regeneration
Precision medicine 2.0 diagnostics
Nanopore episequencing cfDNA
Critical illness
Experimental surgery
Bone histomorphometry
Biochemical analysis
Biomedical Laboratory
Spectrometric Analyses
Experimental surgery
Animal follow-up
Bone histomorphometry
Ferroptosis
Anti-cancer therapeutics
Mechanisms of vascular calcification
Ferroptosis
Multiple sclerosis
Administration
Biochemical analysis
Nephrectomy induced repair
Toxin induced nephropathy
Arterial stiffness in vascular calcification
Metformin
Chronic kidney disease
Ferroptosis
Anti-cancer therapeutics
Ferroptosis
Immunogenicity
Ferroptosis
Multi organ failure
Experimental surgery
Mouse manager
Standard lab analysis
Postdoctoral fellow
Bone histomorphometry
| Title | Cited by |
|
2025
RIPK1 ablation in T cells results in spontaneous enteropathy and TNF-driven villus atrophy
EMBO reports, 1-29, 2025
|
0
|
|
2025
The Efficacy of Ferroptosis Inhibition on Ischemia–Reperfusion Injury of Abdominal Organs: A Systematic Review and Meta-analysis
Transplantation, 10.1097, 2025
|
0
|
|
2025
Macrophage caspase-8 inhibition accelerates necrotic core expansion in atheroma plaque in mice
Frontiers in Immunology 16, 1513637, 2025
|
0
|
|
2025
Harnessing ferroptosis for precision oncology: challenges and prospects
BMC biology 23 (1), 57, 2025
|
3
|
|
2025
Oxazole-Based Ferroptosis Inhibitors with Promising Properties to Treat Central Nervous System Diseases
Journal of Medicinal Chemistry, 2025
|
0
|
|
2025
Intravenous iron treatment fuels chronic kidney disease‐induced arterial media calcification in rats
The Journal of Pathology 265 (2), 172-183, 2025
|
0
|
|
2024
Improving cardiac differentiation of human pluripotent stem cells by targeting ferroptosis
Regenerative Therapy 27, 21-31, 2024
|
0
|
|
2024
Intrinsic temperature increase drives lipid metabolism towards ferroptosis evasion and chemotherapy resistance in pancreatic cancer
Nature communications 15 (1), 8540, 2024
|
1
|
|
2024
Ferroptosis is a targetable detrimental factor in metabolic dysfunction-associated steatotic liver disease
Cell Death & Differentiation 31 (9), 1113-1126, 2024
|
11
|
|
2024
A guide to ferroptosis, the biological rust of cellular membranes
The FEBS journal 291 (13), 2767-2783, 2024
|
16
|
|
2024
RIPK1 protects naive and regulatory T cells from TNFR1-induced apoptosis
Cell Death & Differentiation 31 (6), 820-832, 2024
|
4
|
|
2024
Ferroptosis in health and disease
Redox biology, 103211, 2024
|
86
|
|
2024
Therapeutic exploitation of ferroptosis
Biochemical Society Transactions 52 (2), 693-706, 2024
|
1
|
|
2024
Emerging role of ferroptosis in metabolic dysfunction-associated steatotic liver disease: revisiting hepatic lipid peroxidation
EBioMedicine 102, 2024
|
25
|
|
2024
Loss of PPARα function promotes epigenetic dysregulation of lipid homeostasis driving ferroptosis and pyroptosis lipotoxicity in metabolic dysfunction associated Steatotic …
Frontiers in molecular medicine 3, 1283170, 2024
|
2
|
|
2023
Beyond ferrostatin-1: a comprehensive review of ferroptosis inhibitors
Trends in Pharmacological Sciences 44 (12), 902-916, 2023
|
88
|
|
2023
Effect of erythrophagocytosis-induced ferroptosis during angiogenesis in atherosclerotic plaques
Angiogenesis 26 (4), 505-522, 2023
|
30
|
|
2023
Ferroptosis and pyroptosis signatures in critical COVID-19 patients
Cell Death & Differentiation 30 (9), 2066-2077, 2023
|
19
|
|
2023
Ferroptosis contributes to multiple sclerosis and its pharmacological targeting suppresses experimental disease progression
Cell Death & Differentiation 30 (9), 2092-2103, 2023
|
51
|
|
2023
Zonated quantification of immunohistochemistry in normal and steatotic livers
Virchows Archiv 482 (6), 1035-1045, 2023
|
8
|
| Number | Name | Date |
| US9862678, WO2016075330, EP3218357 | 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death | 2014-11-14 |
| WO2019154795, EP3749645, CN112105601, US20210094909, 201980012162.8 | 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.g. stroke | 2018-02-07 |
| WO2015110346, US9919048 | Targeting of interleukin-1 and -18 signaling in treatment of septic shock | 2014-01-21 |
| EP22196811 | Phenothiazine-based new ferroptosis inhibitors | 2022-09-21 |
| EP24187618.4 | Novel ferroptosis inhibitors - 2024 016 Ferropcam | 2024-07-10 |
| EP24187620.0 | Novel ferroptosis inhibitors - 2024 017 Alferopcom | 2024-07-10 |
| EP24187621.8 | Novel ferroptosis inhibitors - 2024 018 Oxaferropcom | 2024-07-10 |
